AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 1857725 — intervention group
Group type: COMPARATOR
Intervention: Calcium deprivation
Number of subjects: 12
Study 1857725 — intervention group
Group type: COMPARATOR
Intervention: Calcium loading
Number of subjects: 12
Study 1857725 — intervention group
Group type: COMPARATOR
Intervention: Low and high Ca intake
Number of subjects: 12
Study 6342770 — intervention group
Group type: EXPERIMENTAL
Intervention: MCP (100 mg) plus dexamethasone (DM; 48 mg) iv
Number of subjects: 26
Study 6342770 — intervention group
Group type: COMPARATOR
Intervention: MCP (100 mg) plus placebo
Number of subjects: 26
Study 30379348 — intervention group
Group type: EXPERIMENTAL
Intervention: Dampness and mold exposure (including signs such as mold, damp stains, damp bed clothing, water damage, window pane condensation, mold odor, humid air)
Number of subjects: 36541
Study 30379348 — intervention group
Group type: EXPERIMENTAL
Intervention: Mold odor
Number of subjects: 36541
Study 30379348 — intervention group
Group type: EXPERIMENTAL
Intervention: Humid air
Number of subjects: 36541
Study 28299831 — intervention group
Group type: EXPERIMENTAL
Intervention: Ageratina pichinchensis extract (7% standardized, intravaginally administered for 6 days)
Number of subjects: 0
Study 28299831 — intervention group
Group type: COMPARATOR
Intervention: Clotrimazole (100 mg, positive control)
Number of subjects: 0
Study 26755682 — intervention group
Group type: EXPERIMENTAL
Intervention: Frailty Index (FI) classification
Number of subjects: 9306
Study 23529834 — intervention group
Group type: EXPERIMENTAL
Intervention: Compound Phyllanthus Urinaria L. (CPUL) for 3 years
Number of subjects: 102
Study 23529834 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 102
Study 21739267 — intervention group
Group type: EXPERIMENTAL
Intervention: Coadministration of paroxetine (20 mg/day) with aripiprazole (3 mg)
Number of subjects: 28
Study 21739267 — intervention group
Group type: EXPERIMENTAL
Intervention: Coadministration of fluvoxamine (100 mg/day) with aripiprazole (3 mg)
Number of subjects: 28
Study 21739267 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP2D6 EMs with paroxetine
Number of subjects: 28
Study 21739267 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP2D6 IMs with paroxetine
Number of subjects: 28
Study 21739267 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP2D6 EMs with fluvoxamine
Number of subjects: 28
Study 21739267 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP2D6 IMs with fluvoxamine
Number of subjects: 28
Study 19125322 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole for 6 months
Number of subjects: 42
Study 17970679 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.12% chlorhexidine gluconate rinsing
Number of subjects: 20
Study 14726421 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol weaning
Number of subjects: 299
Study 14726421 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 299
Study 12230023 — intervention group
Group type: EXPERIMENTAL
Intervention: Kakkon-to (7.5 g daily for 3 days before surgery, the day of surgery, and for 7 days after surgery)
Number of subjects: 27
Study 12230023 — intervention group
Group type: EXPERIMENTAL
Intervention: Sairei-to (9.0 g daily for 3 days before surgery, the day of surgery, and for 7 days after surgery)
Number of subjects: 27
Study 12230023 — intervention group
Group type: COMPARATOR
Intervention: Untreated right eyes (control group)
Number of subjects: 27
Study 9718972 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine 5 mg (for children weighing less than 30 kg) or 10 mg (for children weighing more than 30 kg) once daily for 15 days
Number of subjects: 30
Study 9718972 — intervention group
Group type: EXPERIMENTAL
Intervention: Levocabastine 2 puffs BID on each nostril for 15 days
Number of subjects: 30
Study 7638127 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoproterenol sensitized head-up tilt test (bolus of isoproterenol 2, 4, 6 and 8 micrograms starting 30 minutes after the beginning of the test)
Number of subjects: 30
Study 7638127 — intervention group
Group type: COMPARATOR
Intervention: Non-sensitized head-up tilt test (no presensitization)
Number of subjects: 30
Study 7638127 — intervention group
Group type: COMPARATOR
Intervention: Non-sensitized head-up tilt test
Number of subjects: 30
Study 7638127 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoproterenol sensitized head-up tilt test
Number of subjects: 30
Study 2512632 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine (dosing at early evening)
Number of subjects: 0
Study 2512632 — intervention group
Group type: EXPERIMENTAL
Intervention: Nizatidine (dosing at early evening)
Number of subjects: 0
Study 2512632 — intervention group
Group type: COMPARATOR
Intervention: Placebo (dosing at early evening)
Number of subjects: 0
Study 2512632 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine (dosing at nighttime)
Number of subjects: 0
Study 2512632 — intervention group
Group type: EXPERIMENTAL
Intervention: Nizatidine (dosing at nighttime)
Number of subjects: 0
Study 2512632 — intervention group
Group type: COMPARATOR
Intervention: Placebo (dosing at nighttime)
Number of subjects: 0
Study 4613503 — intervention group
Group type: EXPERIMENTAL
Intervention: WR 33 063
Number of subjects: 0
Study 4613503 — intervention group
Group type: EXPERIMENTAL
Intervention: WR 30 090
Number of subjects: 0
Study 4613503 — intervention group
Group type: EXPERIMENTAL
Intervention: Other compounds
Number of subjects: 0
Study 30967148 — intervention group
Group type: EXPERIMENTAL
Intervention: Artefenomel (OZ439) - piperaquine (PPQ)
Number of subjects: 0
Study 30967148 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 29178923 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided self-determination-young (GSD-Y) intervention with seven individual education visits over 3 to 6 months
Number of subjects: 100
Study 29178923 — intervention group
Group type: COMPARATOR
Intervention: Standard care including regular visits to the diabetes clinic
Number of subjects: 100
Study 26138546 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Efficiency Online Hemodiafiltration (HDF)
Number of subjects: 72
Study 26138546 — intervention group
Group type: COMPARATOR
Intervention: High-Flux Dialysis (HF)
Number of subjects: 72
Study 23375965 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4 g intravenous immunoglobulin per kg every 2 weeks
Number of subjects: 55
Study 23375965 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 g intravenous immunoglobulin per kg every 4 weeks
Number of subjects: 55
Study 23375965 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 g intravenous immunoglobulin per kg every 4 weeks
Number of subjects: 55
Study 23375965 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.8 g intravenous immunoglobulin per kg every 4 weeks
Number of subjects: 55
Study 23375965 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 g intravenous immunoglobulin per kg every 2 weeks
Number of subjects: 55
Study 23375965 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25 g intravenous immunoglobulin per kg every 2 weeks
Number of subjects: 55
Study 23375965 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study 21854192 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipragliflozin 50 mg
Number of subjects: 61
Study 21854192 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipragliflozin 100 mg
Number of subjects: 61
Study 21854192 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipragliflozin 200 mg
Number of subjects: 61
Study 21854192 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipragliflozin 300 mg
Number of subjects: 61
Study 21854192 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study 19358784 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine ER (75-225 mg/d)
Number of subjects: 343
Study 19358784 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 343
Study 16476042 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone Replacement Therapy (HRT) - 2 mg of estradiol plus 1 mg norethisterone acetate (n = 20)
Number of subjects: 60
Study 16476042 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate - 10 mg (n = 18)
Number of subjects: 60
Study 16476042 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of HRT and Alendronate (n = 22)
Number of subjects: 60
Study 14981230 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent-only intervention
Number of subjects: 50
Study 14981230 — intervention group
Group type: COMPARATOR
Intervention: Children-only intervention (Control)
Number of subjects: 50
Study 11320385 — intervention group
Group type: EXPERIMENTAL
Intervention: Vi-rEPA vaccine
Number of subjects: 11091
Study 11320385 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 11091
Study 11320385 — intervention group
Group type: EXPERIMENTAL
Intervention: Vi-rEPA vaccine (1 injection)
Number of subjects: 11091
Study 11320385 — intervention group
Group type: COMPARATOR
Intervention: Placebo (1 injection)
Number of subjects: 11091
Study 9542261 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine (DIANET system)
Number of subjects: 20
Study 9542261 — intervention group
Group type: COMPARATOR
Intervention: Conventional system
Number of subjects: 20
Study 8515109 — intervention group
Group type: EXPERIMENTAL
Intervention: Albendazole (200 mg; n = 11)
Number of subjects: 23
Study 8515109 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 12)
Number of subjects: 23
Study 3032394 — intervention group
Group type: EXPERIMENTAL
Intervention: 4000 cGy continuous course
Number of subjects: 551
Study 3032394 — intervention group
Group type: EXPERIMENTAL
Intervention: 4000 cGy split course
Number of subjects: 551
Study 3032394 — intervention group
Group type: EXPERIMENTAL
Intervention: 5000 cGy continuous course
Number of subjects: 551
Study 3032394 — intervention group
Group type: EXPERIMENTAL
Intervention: 6000 cGy continuous course
Number of subjects: 551
Study 3032394 — intervention group
Group type: COMPARATOR
Intervention: Various groups
Number of subjects: 551
Study 3032394 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenocarcinoma or large cell undifferentiated carcinoma
Number of subjects: 551
Study 3032394 — intervention group
Group type: COMPARATOR
Intervention: All histologic groups
Number of subjects: 551
Study 3032394 — intervention group
Group type: EXPERIMENTAL
Intervention: Squamous cell carcinoma
Number of subjects: 551
Study 3032394 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenocarcinoma
Number of subjects: 551
Study 3032394 — intervention group
Group type: EXPERIMENTAL
Intervention: Large cell carcinoma
Number of subjects: 551
Study 31702699 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate group (200 mL of apple or grape juice every 3 hours)
Number of subjects: 3984
Study 31702699 — intervention group
Group type: COMPARATOR
Intervention: Fasting group (water only)
Number of subjects: 3984
Study 31702699 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate group
Number of subjects: 3984
Study 31702699 — intervention group
Group type: COMPARATOR
Intervention: Fasting group
Number of subjects: 3984
Study 29808711 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive pharmaceutical care
Number of subjects: 53
Study 29808711 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 53
Study 27654648 — intervention group
Group type: EXPERIMENTAL
Intervention: Chewing gum three times daily from day 1 until discharge
Number of subjects: 82
Study 27654648 — intervention group
Group type: COMPARATOR
Intervention: Standardized recovery programme
Number of subjects: 82
Study 23996482 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib, adriamycin, dexamethasone (PAD)
Number of subjects: 827
Study 23996482 — intervention group
Group type: COMPARATOR
Intervention: Vincristine, adriamycin, dexamethasone (VAD)
Number of subjects: 827
Study 22883843 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4 NDF
Number of subjects: 19
Study 22883843 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.0 NDF
Number of subjects: 19
Study 20117455 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 18549685 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetrorelix at incremental dose (0.25 mg per day increasing to 0.5 mg)
Number of subjects: 0
Study 18549685 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetrorelix at high dose (0.5 mg per day)
Number of subjects: 0
Study 12009014 — intervention group
Group type: EXPERIMENTAL
Intervention: Jumping intervention (10 minutes, 3 times per week)
Number of subjects: 121
Study 12009014 — intervention group
Group type: EXPERIMENTAL
Intervention: Jumping intervention
Number of subjects: 121
Study 12009014 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 121
Study 9893076 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg daily micronized DHEA
Number of subjects: 15
Study 9893076 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg daily micronized DHEA
Number of subjects: 15
Study 9893076 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg, 100 mg, or 200 mg daily micronized DHEA
Number of subjects: 15
Study 9893076 — intervention group
Group type: EXPERIMENTAL
Intervention: DHEA therapy
Number of subjects: 15
Study 7776164 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled de-epithelialization with the carbon dioxide laser at the time of flap surgery and at 10-day intervals over the first 30 days of healing.
Number of subjects: 2
Study 7776164 — intervention group
Group type: COMPARATOR
Intervention: Open debridement only (control group).
Number of subjects: 2
Study 2110411 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 micrograms TRH
Number of subjects: 2
Study 2110411 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 2
Study 876324 — intervention group
Group type: EXPERIMENTAL
Intervention: Antacid regimen
Number of subjects: 74
Study 876324 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74
Study 30538299 — intervention group
Group type: EXPERIMENTAL
Intervention: 30% calorie-reduced intake diet
Number of subjects: 80
Study 30538299 — intervention group
Group type: EXPERIMENTAL
Intervention: Step-count device to monitor physical activity
Number of subjects: 80
Study 30538299 — intervention group
Group type: COMPARATOR
Intervention: Activity advice only
Number of subjects: 80
Study 30538299 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin dosage reduction
Number of subjects: 80
Study 30538299 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle interventions tailored to needs
Number of subjects: 80
Study 28074788 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg/kg intravenous unfractionated heparin
Number of subjects: 62
Study 28074788 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg/kg intravenous unfractionated heparin
Number of subjects: 62
Study 24988118 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily 7000 IU vitamin D3 supplementation
Number of subjects: 58
Study 24988118 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study 23764912 — intervention group
Group type: EXPERIMENTAL
Intervention: Botox® 100 MU (B100)
Number of subjects: 51
Study 23764912 — intervention group
Group type: COMPARATOR
Intervention: Botox® 50 MU (B50)
Number of subjects: 51
Study 23764912 — intervention group
Group type: COMPARATOR
Intervention: Botox® 100 MU (B100) and Botox® 50 MU (B50)
Number of subjects: 51
Study 21777268 — intervention group
Group type: EXPERIMENTAL
Intervention: Regenerative strategy applied to 25 hopeless teeth
Number of subjects: 50
Study 21777268 — intervention group
Group type: COMPARATOR
Intervention: Extraction of 25 hopeless teeth and replacement with conventional or implant-supported fixed partial dentures
Number of subjects: 50
Study 18438234 — intervention group
Group type: EXPERIMENTAL
Intervention: CPS (5 g Cr + 4 g phosphate)
Number of subjects: 32
Study 18438234 — intervention group
Group type: COMPARATOR
Intervention: Placebo (20 g dextrose)
Number of subjects: 32
Study 16937604 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking intervention (3 miles a day, 3 days a week) for 16 weeks in White exercisers (WE)
Number of subjects: 75
Study 16937604 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking intervention (3 miles a day, 3 days a week) for 16 weeks in African American exercisers (AAE)
Number of subjects: 75
Study 16937604 — intervention group
Group type: COMPARATOR
Intervention: Control group (AAC)
Number of subjects: 75
Study 16937604 — intervention group
Group type: COMPARATOR
Intervention: Control group (WC)
Number of subjects: 75
Study 14516297 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine (CQ)
Number of subjects: 683
Study 14516297 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfadoxine-pyrimethamine (SP)
Number of subjects: 683
Study 10868712 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (750 microg twice daily via Diskus)
Number of subjects: 60
Study 10868712 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide (800 microg twice daily via Turbuhaler)
Number of subjects: 60
Study 10868712 — intervention group
Group type: COMPARATOR
Intervention: Beclomethasone dipropionate (BDP) or budesonide (1500-1600 microg day(‐1)) during run-in and washout periods
Number of subjects: 60
Study 9195572 — intervention group
Group type: EXPERIMENTAL
Intervention: Flow Cytometry (FCM)
Number of subjects: 104
Study 9195572 — intervention group
Group type: EXPERIMENTAL
Intervention: Image Cytometry (ICM)
Number of subjects: 104
Study 9195572 — intervention group
Group type: EXPERIMENTAL
Intervention: Both ICM and FCM
Number of subjects: 104
Study 1399547 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen sodium (NPX)
Number of subjects: 79
Study 1399547 — intervention group
Group type: COMPARATOR
Intervention: Ergotamine tartrate (ERG)
Number of subjects: 79
Study 2860157 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% PVP‐I cream
Number of subjects: 0
Study 2860157 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% PVP‐I ointment mixed with a proteolytic agent
Number of subjects: 0
Study 2860157 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% PVP‐I cream with proteolytic agent
Number of subjects: 0
Study 2860157 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 31168604 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote patient monitoring (RPM) plus a yearly in-clinic ICD check-up
Number of subjects: 595
Study 31168604 — intervention group
Group type: COMPARATOR
Intervention: In-clinic check-ups alone (3-6 months)
Number of subjects: 595
Study 31168604 — intervention group
Group type: EXPERIMENTAL
Intervention: RPM
Number of subjects: 595
Study 28772248 — intervention group
Group type: EXPERIMENTAL
Intervention: Camel Snus Winterchill and Robust (5 min trial)
Number of subjects: 151
Study 28772248 — intervention group
Group type: EXPERIMENTAL
Intervention: Product Evaluation Scale (PES) and Drug Effects Questionnaire (DEQ) ratings
Number of subjects: 151
Study 28772248 — intervention group
Group type: EXPERIMENTAL
Intervention: Camel Snus (1 unit per day or at least 7 pouches total)
Number of subjects: 151
Study 27075314 — intervention group
Group type: EXPERIMENTAL
Intervention: NRL001 5 mg
Number of subjects: 466
Study 27075314 — intervention group
Group type: EXPERIMENTAL
Intervention: NRL001 7.5 mg
Number of subjects: 466
Study 27075314 — intervention group
Group type: EXPERIMENTAL
Intervention: NRL001 10 mg
Number of subjects: 466
Study 27075314 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 466
Study 27075314 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (including NRL001 and placebo)
Number of subjects: 466
Study 24588133 — intervention group
Group type: EXPERIMENTAL
Intervention: Immersive semester-long simulation exercise
Number of subjects: 0
Study 24588133 — intervention group
Group type: EXPERIMENTAL
Intervention: Facilitated tabletop exercises
Number of subjects: 0
Study 23163146 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture anesthesia (AA)
Number of subjects: 61
Study 23163146 — intervention group
Group type: COMPARATOR
Intervention: Local anesthesia (LA)
Number of subjects: 61
Study 20684941 — intervention group
Group type: EXPERIMENTAL
Intervention: Random practice (dissimilar parameter condition)
Number of subjects: 60
Study 20684941 — intervention group
Group type: COMPARATOR
Intervention: Blocked practice (dissimilar parameter condition)
Number of subjects: 60
Study 20684941 — intervention group
Group type: EXPERIMENTAL
Intervention: Random practice (similar parameter condition)
Number of subjects: 60
Study 20684941 — intervention group
Group type: COMPARATOR
Intervention: Blocked practice (similar parameter condition)
Number of subjects: 60
Study 17051504 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritonavir-boosted tipranavir (TPV/r)
Number of subjects: 863
Study 17051504 — intervention group
Group type: COMPARATOR
Intervention: Ritonavir-boosted protease inhibitor (CPI/r)
Number of subjects: 863
Study 12616120 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical bowel preparation with polyethylene glycol (Group A)
Number of subjects: 380
Study 12616120 — intervention group
Group type: COMPARATOR
Intervention: No mechanical bowel preparation (Group B)
Number of subjects: 380
Study 11259932 — intervention group
Group type: EXPERIMENTAL
Intervention: kHz frequency alternating current (1-15 kHz, interrupted at 50 Hz, applied in 3-s surges for 10 minutes)
Number of subjects: 0
Study 11259932 — intervention group
Group type: EXPERIMENTAL
Intervention: kHz frequency alternating current
Number of subjects: 0
Study 10170449 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil + propofol
Number of subjects: 26
Study 10170449 — intervention group
Group type: COMPARATOR
Intervention: Morphine + midazolam
Number of subjects: 26
Study 7524379 — intervention group
Group type: EXPERIMENTAL
Intervention: Reogluman administration
Number of subjects: 0
Study 7524379 — intervention group
Group type: COMPARATOR
Intervention: Reference patients (control group)
Number of subjects: 0
Study 3091188 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritanserin (5-HT2 antagonist)
Number of subjects: 0
Study 3091188 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30606085 — intervention group
Group type: EXPERIMENTAL
Intervention: Veinplicity
Number of subjects: 20
Study 30606085 — intervention group
Group type: COMPARATOR
Intervention: Heat packs
Number of subjects: 20
Study 29414272 — intervention group
Group type: EXPERIMENTAL
Intervention: Prazosin
Number of subjects: 304